SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system

Abstract Background Sodium glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of heart failure and new data show they can prevent atrial fibrillation (AF). We examined the association between SGLT2i and AF in the Food and Drug Administration adverse event reporting system (FAERS). Methods W...

Full description

Bibliographic Details
Main Authors: Benedetta Maria Bonora, Emanuel Raschi, Angelo Avogaro, Gian Paolo Fadini
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Cardiovascular Diabetology
Subjects:
Pharmacovigilance
Epidemiology
Complications
Observational
Type 2 diabetes
Clinical practice
Online Access:https://doi.org/10.1186/s12933-021-01243-4

Internet

https://doi.org/10.1186/s12933-021-01243-4

Similar Items